Cronus Pharma Launches Butorphic® (Butorphanol Tartrate) Sterile Injectable Solution
"Butorphic is a vital analgesic for managing equine colic pain and we are excited to grow our equine portfolio. Importantly, Butorphic marks our fifth product launch this year, expanding our portfolio to twenty-five products with several more planned for 2025 and beyond," said Vimal Kavuru, Chairman & CEO.
This launch enhances Cronus Pharma's robust sedative and anesthesia product portfolio which includes AnaSed® Equine (Xylazine) Injection, Cropamezole™ (Atipamezole) Injection, DexmedVet™ (Dexmedetomidine) Injection, DetomiSed™ (Detomidine) Injection, and Ketamine Injection.
"Butorphic's launch reinforces our position among the animal health leaders in U.S. FDA ANADA approvals over the past several years, which is a testament to our team's dedication to delivering high-quality, cost-effective pharmaceuticals to veterinarians and pet owners," said Edward Neugeboren, Chief Strategy Officer.
Butorphic is indicated for the relief of pain associated with colic and postpartum pain in adult horses and yearlings. Clinical studies demonstrate that butorphanol tartrate effectively alleviates abdominal pain caused by torsion, impaction, intussusception, spasmodic and tympanic colic, and postpartum pain. Approved by the FDA under ANADA #200-332, Butorphic provides the same efficacy and safety, and is a generic equivalent to the reference product, Torbugesic®. Available in 10 mg/mL concentrations in 20 mL and 50 mL multi-dose vials, our unique 20 mL vial offers veterinarians more flexible dosing options.
Please refer to the Package Insert for complete prescribing instructions, precautions, and full safety information.
About Cronus Pharma
Cronus is a fully integrated research, development, manufacturing, sales and marketing animal health pharmaceutical company headquartered in East Brunswick, New Jersey, dedicated to providing high-quality and cost-effective pharmaceuticals serving the companion, equine and production animal health markets. Through our in-house R&D and acquisitions, Cronus has an extensive product portfolio of seventy-seven US FDA approved products as well as numerous products pending approval and a broad development pipeline. Cronus is proud to be among the leaders in U.S FDA ANADA approvals in the animal health industry over the past several years. Our recently built state of the art manufacturing facility located in Hyderabad, India has broad capabilities including solid oral dose, sterile injectables and cephalosporins. Our products are available to veterinarians and pet owners nationwide through national and regional distributors. Our passionate team is committed to growing our business and being among the leading animal health pharmaceutical companies.
Additional information is available at www.cronuspharmausa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
We recently compiled a list of Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most undervalued stocks. It is a leading American biotech company specializing in treatments for serious diseases across ophthalmology, immunology, oncology, and rare conditions. The company is known for integrating genetics and technology into its drug discovery efforts and continues to grow through internal innovation and strategic acquisitions. In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe's assets for $256 million, including its personal genome service, research services, biobank, and associated data. This will expand the business's access to genetic information from 15 million individuals (with 80% consenting to research use), enhancing its existing warehouse of 3 million anonymized samples. The acquisition significantly boosts Regeneron's capabilities in genetics-guided drug development and precision medicine. The vast dataset will help identify new drug targets, refine clinical trial designs, and improve patient stratification. This positions the corporation to lead the integration of real-world genomic data into personalized healthcare. A pharmacist at work in their online pharmacy checking over orders for pharmaceutical products. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) continues to advance its pipeline with FDA priority reviews for Dupixent (bullous pemphigoid) and Linvoseltamab (multiple myeloma), as well as promising late-stage results for EYLEA HD in eye disorders. The firm's focus remains on leveraging data and science to drive innovative, effective therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
2 days ago
- New York Post
New Mexico Pinon Coffee recalls pods due to contamination risk
A New Mexico coffee company is recalling its single-serve cups due to contamination concerns. The company, New Mexico Pinon Coffee, said it is voluntarily recalling one lot of its New Mexico Pinon Coffee Dark Pinon Single Serve Cups in a 10-count box. Advertisement The single-serve cups are filled with ground coffee flavored with natural flavorings. The affected batch is about 154 Dark Pinon 10ct Single Serve cups. The Food and Drug Administration (FDA) described the issue, saying the clear coat seal on the lid of the single-serve cups did not get applied consistently to all cups in the production run and could cause food coloring to run into the cup during brewing. The company didn't receive any reports of illnesses or injuries associated with the product. Advertisement Still, the company said it is recalling the product out of an abundance of caution. The product was sold on Amazon, according to its website. No other New Mexico Pinon Coffee products have been impacted by the recall. Consumers that have purchased these products are asked to either throw away or return the product for a refund. Advertisement New Mexico Pinon Coffee voluntarily recalled one lot of its New Mexico Pinon Coffee Dark Pinon Single Serve Cups in a 10-count box. REUTERS The company recalled the product out of an abundance of caution. New Mexico Pinon Coffee / Facebook 'At New Mexico Piñon Coffee, quality means everything to us,' the company told FOX Business in a statement. 'While the issue was isolated and poses no health risk, it didn't meet the standard of excellence you've come to expect from us.' Advertisement The company said it has already addressed the issue and taken steps to refine its process moving forward. The recall has been deemed a Class III, which is when situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences, according to the FDA.
Yahoo
2 days ago
- Yahoo
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Sign in to access your portfolio
